NOB works predominantly as a retinoic acid receptor-related orphan receptor (ROR) agonist, and has been shown to have anti-tumor effects in the context of triple negative breast cancer, where it alters NF-κB activity in a ROR-dependent manner (Kim et al., 2022). This evidence concerns the gene NFKB1 and triple-negative breast carcinoma.